Baxter (BAX) reports Q4 EPS of $0.97, not providing guidance for full-year 2020
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq hits intraday record high on Alphabet boost, Mideast negotiation hopes
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Oil falls to two-week low as Gulf supply outlook improves
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Baxter Reports Fourth-Quarter and Full-Year 2019 Results, Completes Financial Restatement Process
March 17, 2020 7:25 AM EDTFourth-quarter sales of $3.0 billion increased 7% on a reported basis and 9% on an operational basis1 Fourth-quarter GAAP earnings per share (EPS) were a loss of $0.05; adjusted EPS1 totaled $0.97 Full-year sales of $11.4 billion increased 2% on a reported basis and 5% on an operational basis Full-year GAAP EPS were $1.93; adjusted EPS totaled $3.31 With submission of restated financials, company is now current in its SEC reporting obligations
DEERFIELD, Ill.--(BUSINESS WIRE)-- Baxter International Inc. (NYSE: BAX), a leading global medical products company, today announced its complete... More
